← back to search

Sabine Semrau

National Center for Tumor Diseases ·
Area of research
Otorhinolaryngology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Radiation therapy, Durvalumab, Tremelimumab, Internal medicine, and Head and neck cancer.
h-index
citations
851
works
20
NIH funding
primary concept
email

Recent publications

Does Size Outweigh Number in Predicting Survival After Pulmonary Metastasectomy for Soft Tissue Sarcoma? Insights from a Retrospective Multicenter Study
Annals of Surgical Oncology 2025cited by 5position: middledoi
The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
Journal of Cancer Research and Clinical Oncology 2025cited by 4position: middledoi
Head and neck squamous cell carcinoma in adults aged 45 or younger—an analysis of two tertiary cancer centres
Strahlentherapie und Onkologie 2025cited by 1position: middledoi
De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status—results of a prospective multicenter phase II trial (DIREKHT Trial)
Frontiers in Oncology 2024cited by 13position: middledoi
Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma – A retrospective multicenter study of the Bavarian university hospitals
European Journal of Surgical Oncology 2024cited by 7position: middledoi
Machine Learning–Supported Diagnosis of Small Blue Round Cell Sarcomas Using Targeted RNA Sequencing
Journal of Molecular Diagnostics 2024cited by 5position: middledoi
The health-related quality of life of sarcoma patients treated with neoadjuvant versus adjuvant radiotherapy – Results of a multi-center observational study
Radiotherapy and Oncology 2023cited by 2position: middledoi
Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
Journal of Clinical Oncology 2022cited by 114position: middledoi
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer
Journal for ImmunoTherapy of Cancer 2022cited by 45position: middledoi
F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial
Annals of Nuclear Medicine 2022cited by 7position: lastdoi
Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial.
Journal of Clinical Oncology 2022cited by 3position: middledoi
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer
Cancers 2021cited by 22position: firstdoi
Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.
Journal of Clinical Oncology 2021cited by 15position: middledoi
Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice
Strahlentherapie und Onkologie 2021cited by 9position: middledoi
Reduction of Elective Radiotherapy Treatment Volume in Definitive Treatment of Locally Advanced Head and Neck Cancer—Comparison of a Prospective Trial with a Revised Simulated Contouring Approach
Journal of Clinical Medicine 2021cited by 5position: middledoi
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
Journal for ImmunoTherapy of Cancer 2020cited by 87position: middledoi
A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).
Journal of Clinical Oncology 2020cited by 2position: middledoi
SMARCB1 (INI-1)-deficient Sinonasal Carcinoma
The American Journal of Surgical Pathology 2017cited by 251position: middledoi
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
Annals of Oncology 2015cited by 129position: middledoi
Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy
Radiotherapy and Oncology 2015cited by 125position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Heinrich Iro · Friedrich-Alexander-Universität Erlangen-Nürnberg9 papers (2017–2022)Jens von der Grün · University of Zurich9 papers (2020–2022)Rainer Fietkau · Bayer (Germany)8 papers (2020–2022)Arndt Hartmann · Methodist University8 papers (2017–2024)Markus Hecht · Friedrich-Alexander-Universität Erlangen-Nürnberg8 papers (2015–2022)Matthias Hautmann · University of Regensburg8 papers (2020–2022)Markus Eckstein · Centro de Investigación del Cáncer8 papers (2020–2022)Antoniu‐Oreste Gostian · Friedrich-Alexander-Universität Erlangen-Nürnberg8 papers (2020–2022)Udo S. Gaipl · DKFZ-ZMBH Alliance8 papers (2020–2022)Günther Klautke · Friedrich-Alexander-Universität Erlangen-Nürnberg7 papers (2020–2022)Benjamin Frey · DKFZ-ZMBH Alliance7 papers (2020–2022)Thomas Illmer · Ludwig-Maximilians-Universität München7 papers (2020–2022)Thomas Brunner · University of Konstanz7 papers (2020–2022) · 6 papers (2020–2022)Panagiotis Balermpas · University of Zurich6 papers (2020–2022)Simon Laban · Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde6 papers (2020–2022)Wilfried Budach · Life Science Center Düsseldorf (Germany)6 papers (2020–2022)Sandra Rutzner · Friedrich-Alexander-Universität Erlangen-Nürnberg6 papers (2020–2022)Axel Hinke · Hochschule Düsseldorf University of Applied Sciences5 papers (2020–2022)Rainer Fietkau · Immunomedics (Germany)4 papers (2015–2023)